Catalyst Pharmaceuticals named one of Forbes’ 2022 America’s Best Small Companies

Catalyst Pharmaceuticals, Inc.

The company ranked 65th out of more than 1,000 companies evaluated

CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric, licensing-focused biopharmaceutical company, developing, and bringing to market new, high-quality drugs for patients with rare diseases, today announced that the company has been named Forbes 2022 “America’s Best Small Companies” in its recently released list. The Company was ranked 65th out of more than 1,000 companies assessed.

“It’s a great honor to be recognized by Forbes as one of the best small businesses in the country,” said Patrick J. McEnany, president and CEO of Catalyst. “Our strong operational and financial performance is a result of our exceptional business and strategic execution. The recognition of the value we create is very gratifying, and I want to thank all of our employees who share a commitment to the rare disease patients we serve. . “

The annual Forbes 2022 America’s Best Small-Cap Companies list was compiled using data from FactSet. Once collected, more than 1,000 companies listed on the stock exchange for more than a year with a market value between $300 million and $2 billion were reviewed to find 509 companies that experienced positive sales growth over the course of the year. for the past 12 months and a share price of at least $5. . The top 100 rankings are based on earnings growth, sales growth, return on equity and total stock return for the last 12 months available and the last five years. More weight was given to data from the last year in the ranking.

For Forbes’ full list of Best Small Businesses, visit

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a patient-centric, commercial-stage biopharmaceutical company focused on licensing, developing and commercializing new, high-quality drugs for patients with rare diseases. With a focus on patients, Catalyst is committed to building a strong pipeline of breakthrough, first-in-class, or first-in-class medicines for other rare diseases. Catalyst’s New Drug Application for FIRDAPSE® (amifampridine) tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (“LEMS”) was approved in 2018 by the Food & Drug Administration (“FDA ”) from the United States, and FIRDAPSE is marketed available in the United States as a treatment for adults with LEMS. In addition, Canada’s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Forward-looking statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from anticipated results. A number of factors, including those described in Catalyst’s Annual Report on Form 10-K for Fiscal Year 2020 and its other filings with the United States Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be viewed on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst assumes no obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

CONTACT: Media Contact David Schull Russo Partners (858) 717-2310 [email protected] Investor Contact Mary Coleman Catalyst Pharmaceuticals, Inc. (305) 420-3200 [email protected]

Comments are closed.